|
Aug 16
|
2 Top Dividend Stocks to Buy on the Dip
|
|
Aug 15
|
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer
|
|
Aug 15
|
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
|
|
Aug 15
|
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey
|
|
Aug 15
|
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
|
|
Aug 15
|
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
|
|
Aug 15
|
Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers
|
|
Aug 14
|
Top Analyst Reports for Merck, Palo Alto & Freeport
|
|
Aug 14
|
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
|
|
Aug 13
|
China pharma firms turn to local reagent suppliers to cut costs and delivery times
|
|
Aug 13
|
3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever
|
|
Aug 13
|
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
|
|
Aug 13
|
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
|
|
Aug 13
|
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
|
|
Aug 13
|
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
|
|
Aug 13
|
Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Withou...
|
|
Aug 13
|
Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation
|
|
Aug 13
|
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
|
|
Aug 13
|
5 Must-Read Analyst Questions From Merck’s Q2 Earnings Call
|
|
Aug 12
|
Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment
|